Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Meet the Experts Special: Biotech in Australia and New Zealand




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Meet the Experts Special: Biotech in Australia and New Zealand
Released on: January 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this ‘Meet the Experts’ special, Fintan Walton is joined on the panel by Colin Dawson, CEO of Otago Innovation and David Williams, CEO of Chemeq.
  • Summary
  • Transcript
  • Company
In this ‘Meet the Experts’ special, Fintan Walton is joined on the panel by Colin Dawson, CEO of Otago Innovation and David Williams, CEO of Chemeq. Together, they discuss a variety of important issues that face the biotechnology industry in Australia and New Zealand. They talk about the current climate for early-stage financing of start-up companies and the problems that many companies have when they enter the public markets via the ASX. They also talk about the bidirectional opportunities for partnering Australian or New Zealand companies with their European, US and South-East Asian counterparts.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Otago Innovation
A wholly–owned subsidiary of the University of Otago, Otago Innovation Limited is charged with exclusive responsibility for the commercialisation of Intellectual Property arising from research within the University.
Chemeq Ltd
Chemeq's research and development process discovered the creation of long-chain polymeric aldehydes. Thanks to the large molecular size which limits absorption and tissue residues, long-chain polymeric aldehydes are non-volatile, relatively safe to handle and non-toxic. They also act differently to antibiotics and other biocides, resulting in rapid microbial kill with no evidence of microbial resistance.